Acquisition extends ICON's presence in the market for government
sponsored research and enhances capabilities in Vaccines and Infectious
plc, (NASDAQ:ICLR) a global provider of drug development
solutions and services to the pharmaceutical, biotechnology and medical
device industries, today announced that it has agreed, subject to
certain customary closing conditions (including applicable regulatory
approvals), to acquire Clinical Research Management, Inc. (ClinicalRM).
The acquisition will enhance ICON's ability to access the market for
government sponsored research and further enhances ICON's capabilities
in the areas of Vaccines and Infectious Disease.
ClinicalRM provide full service and functional research solutions to a
broad range of US government agencies. Their extensive expertise extends
across basic and applied research, infectious diseases, vaccines
development and testing and the response to bio-threats. They have
worked in collaboration with government and commercial customers to
respond to the threat of global viral epidemics.
Commenting on the acquisition, ICON's Chief Executive Officer, Ciaran
Murray said: "The market for government sponsored research is
significant with over fifteen hundred active clinical studies being
funded by the National Institutes of Health or other federal agencies.
ClinicalRM has strong relationships and a deep understanding of what is
required to partner successfully with government sponsors. They will
provide ICON a platform to further penetrate this market segment as part
of our strategy to grow and diversify our customer base. ClinicalRM's
experience in responding to the challenges of global viruses will
further enhance ICON's capabilities in the areas of Vaccines and
Infectious disease, benefiting our customers and patients globally."
Victoria Tifft, Chief Executive Officer of ClinicalRM added, "We are
delighted to be joining ICON. By combining ClinicalRM's expertise in
government sponsored research with ICON's breadth of services and global
footprint we will be able to bring additional services and thought
leadership to our customers. We are also excited about the potential the
combination has to further innovate drug development in the area of
Vaccines and Infectious diseases, important areas of focus for both
government and commercial customers."
ClinicalRM is a full-service Contract Research Organization specializing
in preclinical through Phase IV support of clinical research and
clinical trial services for biologics, drugs and devices. The
organization helps customers get their products to market faster with a
wide array of research, regulatory and sponsor services within the U.S.
and around the globe. From international partnerships and affiliations
to government relations and local alliances, ClinicalRM delivers a
synergy in the global market with projects spanning the government,
academic and commercial marketplaces. The company has a distinct ability
to provide boots-on-the-ground and rapid response efforts to global
health crises. More information is at http://www.clinicalrm.com/.
About ICON plc
ICON plc is a global provider of drug development solutions and services
to the pharmaceutical, biotechnology and medical device industries. The
company specialises in the strategic development, management and
analysis of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. With headquarters in Dublin,
Ireland, ICON currently, operates from 89 locations in 37 countries and
has approximately 12,200 employees.
Further information is available at www.iconplc.com.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in SEC reports filed by ICON, all of which are difficult to
predict and some of which are beyond our control. For these reasons, you
should not place undue reliance on these forward-looking statements when
making investment decisions. The word "expected" and variations of such
words and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at http://www.sec.gov.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160630005430/en/
Niamh Murphy, +35312912180
Source: ICON plc
News Provided by Acquire Media